Literature DB >> 22736575

Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence.

Torsten Passie1, Hinderk M Emrich, Matthias Karst, Simon D Brandt, John H Halpern.   

Abstract

It is known from clinical studies that some patients attempt to cope with the symptoms of post-traumatic stress disorder (PTSD) by using recreational drugs. This review presents a case report of a 19-year-old male patient with a spectrum of severe PTSD symptoms, such as intense flashbacks, panic attacks, and self-mutilation, who discovered that some of his major symptoms were dramatically reduced by smoking cannabis resin. The major part of this review is concerned with the clinical and preclinical neurobiological evidence in order to offer a potential explanation of these effects on symptom reduction in PTSD. This review shows that recent studies provided supporting evidence that PTSD patients may be able to cope with their symptoms by using cannabis products. Cannabis may dampen the strength or emotional impact of traumatic memories through synergistic mechanisms that might make it easier for people with PTSD to rest or sleep and to feel less anxious and less involved with flashback memories. The presence of endocannabinoid signalling systems within stress-sensitive nuclei of the hypothalamus, as well as upstream limbic structures (amygdala), point to the significance of this system for the regulation of neuroendocrine and behavioural responses to stress. Evidence is increasingly accumulating that cannabinoids might play a role in fear extinction and antidepressive effects. It is concluded that further studies are warranted in order to evaluate the therapeutic potential of cannabinoids in PTSD.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22736575     DOI: 10.1002/dta.1377

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  37 in total

1.  Treatment outcomes for veterans with PTSD and substance use: Impact of specific substances and achievement of abstinence.

Authors:  Ajay Manhapra; Elina Stefanovics; Robert Rosenheck
Journal:  Drug Alcohol Depend       Date:  2015-09-25       Impact factor: 4.492

Review 2.  Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks.

Authors:  Mason M Silveira; Jonathon C Arnold; Steven R Laviolette; Cecilia J Hillard; Marta Celorrio; María S Aymerich; Wendy K Adams
Journal:  Neurosci Biobehav Rev       Date:  2016-09-14       Impact factor: 8.989

Review 3.  Risks associated with the non-medicinal use of cannabis.

Authors:  Eva Hoch; Udo Bonnet; Rainer Thomasius; Florian Ganzer; Ursula Havemann-Reinecke; Ulrich W Preuss
Journal:  Dtsch Arztebl Int       Date:  2015-04-17       Impact factor: 5.594

4.  [Cannabinoids in pain medicine].

Authors:  M Karst
Journal:  Schmerz       Date:  2018-10       Impact factor: 1.107

Review 5.  Translational evidence for a role of endocannabinoids in the etiology and treatment of posttraumatic stress disorder.

Authors:  Alexander Neumeister; Jordan Seidel; Benjamin J Ragen; Robert H Pietrzak
Journal:  Psychoneuroendocrinology       Date:  2014-10-22       Impact factor: 4.905

6.  Use of Protective Behavioral Strategies among Young Adult Veteran Marijuana Users.

Authors:  Eric R Pedersen; Margo C Villarosa-Hurlocker; Mark A Prince
Journal:  Cannabis       Date:  2018-01-30

7.  Association of Marijuana Use With Psychosocial and Quality of Life Outcomes Among Patients With Head and Neck Cancer.

Authors:  Han Zhang; Michael Xie; Stuart D Archibald; B Stanley Jackson; Michael K Gupta
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-11-01       Impact factor: 6.223

Review 8.  Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Authors:  Ryan Wyrofsky; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Expert Opin Drug Discov       Date:  2014-12-09       Impact factor: 6.098

9.  Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder.

Authors:  Pablo Roitman; Raphael Mechoulam; Rena Cooper-Kazaz; Arieh Shalev
Journal:  Clin Drug Investig       Date:  2014-08       Impact factor: 2.859

10.  Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed.

Authors:  Margaret Haney; A Eden Evins
Journal:  Neuropsychopharmacology       Date:  2015-08-19       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.